Durability of combination of insulin and GLP-1 receptor agonist or SGLT-2 inhibitors versus basal bolus insulin regimen in type 2 diabetes: a randomized controlled trial - BEYOND

A.O.U. Università degli Studi della Campania Luigi Vanvitelli0 个研究点目标入组 110 人开始时间: 2021年5月24日最近更新: 2021年8月30日

适应症

试验速览

暂无简介。

•Patients on insulin therapy basal bolus stable for at least one year associated or not with metformin
•Insufficient glycemic control (HbA1c> 7.5%
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 110
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 110

•Type 1 diabetes or diabetes secondary to specific causes
•Previous treatment (within the last 3 months) with a GLP-1RA or a DPPIV inhibitor
•Contraindications to the use of GLP-1RA (pancreatitis, gallbladder stones)
•Pregnancy or pregnancy scheduled during the study period
•Serum creatinine> 1.3 mg / dL in women and> 1.4 mg / dL in men
•GFR <30 ml / min
•History of cancer or anti-neoplastic therapy in the 5 years prior to randomization
•Current therapy with oral, topical or systemic glucocorticoids, or with atypical anti-psychotics.

发起方

A.O.U. Università degli Studi della Campania Luigi Vanvitelli